Rani Therapeutics
RANI
36 hedge funds and large institutions have $15.5M invested in Rani Therapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
6% more funds holding
Funds holding: 34 → 36 (+2)
0.21% more ownership
Funds ownership: 11.93% → 12.13% (+0.21%)
12% less capital invested
Capital invested by funds: $17.6M → $15.5M (-$2.15M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
81% less call options, than puts
Call options by funds: $5K | Put options by funds: $26K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$426K |
| 2 |
Goldman Sachs
New York
|
+$202K |
| 3 |
CL
Choreo LLC
Rockford,
Illinois
|
+$149K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$120K |
| 5 |
HF
HRT Financial
New York
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
-$371K |
| 2 |
PCIA
Prime Capital Investment Advisors
Overland Park,
Kansas
|
-$198K |
| 3 |
E
Ergoteles
New York
|
-$106K |
| 4 |
CH
Canton Hathaway
Providence,
Rhode Island
|
-$86K |
| 5 |
Jane Street
New York
|
-$76.3K |
RANI Hedge Fund Activity: Q1 2023 in Review
36 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q1 2023, worth a combined $15.5M — down 12% from $17.6M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RANI positions and 4 closed out — a net gain of 3 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $426K. The largest seller was Alphabet Inc, cutting an estimated $371K.
- 36 institutional investors held Rani Therapeutics (RANI) as of Q1 2023, up from 34 in Q4 2022.
- Funds reported $15.5M of Rani Therapeutics stock for Q1 2023, down 12% quarter-over-quarter.
- 7 funds opened new Rani Therapeutics positions in Q1 2023 and 4 closed out, a net change of +3 holders.
- The largest Rani Therapeutics buyer in Q1 2023 was Susquehanna International Group, an estimated $426K added.
- The largest Rani Therapeutics seller in Q1 2023 was Alphabet Inc, an estimated $371K sold.
Based on aggregated 13F filings for Q1 2023.